Skip to main content
SpringerLink
Log in

The efficacy and safety of selective leukocytapheresis in the treatment of ulcerative colitis: a meta-analysis

  • Original Article
  • Published:
International Journal of Colorectal Disease Aims and scope Submit manuscript

Abstract

Purpose

The use of selective leukocytapheresis for the treatment of ulcerative colitis (UC) has been evaluated in several open and controlled trials, with varying outcomes. A meta-analysis was performed to better assess the efficacy and safety of selective leukocytapheresis as supplemental therapy compared with conventional pharmacotherapy in patients with UC.

Methods

All randomized trials comparing selective leukocytapheresis supplementation with conventional pharmacotherapy were included from electronic databases and reference lists. A meta-analysis that pooled the outcome effects of leukocytapheresis and pharmacotherapy was performed. A fixed effect model or random effect model was selected depending on the heterogeneity test of the trials.

Results

Nine randomized controlled trials met the inclusion criteria contributing a total of 686 participants. Compared with conventional pharmacotherapy, leukocytapheresis supplementation presented a significant benefit in promoting a response rate (OR, 2.88, 95% CI: 1.60–5.18) and remission rate (OR, 2.04; 95% CI, 1.36–3.07) together with significant higher steroid-sparing effects (OR, 10.49; 95% CI, 3.44–31.93) in patients with active moderate-to-severe UC by intention-to-treat analysis. Leukocytapheresis was more effective in maintaining clinical remission for asymptomatic UC patients than conventional therapy (OR, 8.14; 95% CI, 2.22–29.90). The incidence of mild–moderate adverse effects was much less frequent in the leukocytapheresis groups than conventional pharmacotherapy groups (OR, 0.16; 95% CI, 0.04–0.60). Few severe adverse events were observed.

Conclusions

Current data indicate that leukocytapheresis supplementation may be more efficacious on improving response and remission rates and tapering corticosteroid dosage with excellent tolerability and safety than conventional pharmacotherapy in patients with UC. In addition, more high-quality randomized controlled trials are required to confirm the higher efficacy of leukocytapheresis in patients with UC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Rugtveit J, Brandtzaeg P, Halstensen TS (1994) Increased macrophage subsets in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut 35:669–674

    Article  PubMed  CAS  Google Scholar 

  2. Meuret G, Bitzi A, Hammer B (1978) Macrophage turnover in Crohn's disease and ulcerative colitis. Gastroenterol 74:501–503

    CAS  Google Scholar 

  3. Mahida YR (1997) Monocytes and macrophages in inflammatory bowel disease. In: Allan RN, Rhodes JM, Hanauer SB, Keighley MRB, Alexander-Williams J, Fazio VW (eds) Inflamatory bowel diseases, 3rd edn. Churchill Livingstone, New York, pp 81–85

    Google Scholar 

  4. Sharon P, Stenson WF (1984) Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterol 86:453–460

    CAS  Google Scholar 

  5. Balfour S (1994) Cytokines in inflammatory bowel disease: pathophysiology and clinical considerations. Gastroenterol 106:533–539

    Google Scholar 

  6. Nikolaus S, Bauditz J, Gionchetti P (1998) Increased secretion of proinflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin-10 during intestinal inflammation. Gut 42:470–476

    Article  PubMed  CAS  Google Scholar 

  7. Kaplanski G, Marin V, Montero-Julian F (2003) IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol 24:25–29

    Article  PubMed  CAS  Google Scholar 

  8. Hanai H, Watanabe F, Takeuchi K et al (2003) Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol 1:28–35

    Article  PubMed  Google Scholar 

  9. Rembacken BJ, Newbould HE, Richards SJ et al (1998) Granulocyte apheresis in inflammatory bowel disease: possible mechanisms of effect. Ther Apher 2:93–96

    Article  PubMed  CAS  Google Scholar 

  10. Ayabe T, Ashida T, Taniguchi M et al (1997) A pilot study of centrifugal leukocyte apheresis for corticosteroid-resistant active ulcerative colitis. Intern Med 36:322–326

    Article  PubMed  CAS  Google Scholar 

  11. Saniabadi AR, Hanai H, Takeuchi K et al (2003) Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial 7:48–59

    Article  PubMed  Google Scholar 

  12. Hiraishi K, Takeda Y, Shiobara N et al (2003) Studies on the mechanisms of leukocyte adhesion to cellulose acetate beads: an in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte adsorptive apheresis. Ther Apher Dial 7:334–340

    Article  PubMed  Google Scholar 

  13. Sawada K, Ohnishi K, Kosaka T et al (1997) Leukocytapheresis with leukocyte removal filter as new therapy for ulcerative colitis. Ther Apher 1:207–211

    Article  PubMed  CAS  Google Scholar 

  14. Bresci G, Parisi G, Mazzoni A, Scatena F, Capria A (2007) Treatment of patients with acute ulcerative colitis: conventional corticosteroid therapy (MP) versus granulocytapheresis (GMA): a pilot study. Dig Liver Dis 39:430–434

    Article  PubMed  CAS  Google Scholar 

  15. Domènech E, Hinojosa J, Esteve-Comas M et al (2004) Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther 20:1347–1352

    Article  PubMed  Google Scholar 

  16. Shimoyama T, Sawada K, Tanaka T et al (1999) Granulocyte and monocyte apheresis with the G-1 column in the treatment of patients with active ulcerative colitis. Jpn J Apher 18:117–131

    Google Scholar 

  17. Sawada K, Muto T, Shimoyama T et al (2003) Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des 9:307–321

    Article  PubMed  CAS  Google Scholar 

  18. Kjaergard LL, Villumsen J, Gluud C (2001) Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 135:982–989

    PubMed  CAS  Google Scholar 

  19. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634

    PubMed  CAS  Google Scholar 

  20. Hanai H, Watanabe F, Yamada M et al (2004) Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion 70:36–44

    Article  PubMed  CAS  Google Scholar 

  21. Nakamura T, Kawagoe Y, Matsuda T et al (2004) Effect of granulocyte and monocyte adsorption apheresis on urinary albumin excretion and plasma endothelin-1 concentration in patients with active ulcerative colitis. Blood Purif 22:499–504

    Article  PubMed  CAS  Google Scholar 

  22. Bresci G, Parisi G, Mazzoni A, Scatena F, Capria A (2008) Granulocytapheresis versus methylprednisolone in patients with acute ulcerative colitis: 12-month follow up. J Gastroenterol Hepatol 23:1678–1682

    Article  PubMed  CAS  Google Scholar 

  23. Hanai H, Iida T, Takeuchi K et al (2008) Intensive granulocyte and monocyte adsorption versus intravenous prednisolone in patients with severe ulcerative colitis: an unblinded randomised multi-centre controlled study. Dig Liver Dis 40:433–440

    Article  PubMed  CAS  Google Scholar 

  24. Sands BE, Sandborn WJ, Feagan B et al (2008) A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterol 135:400–409

    Article  CAS  Google Scholar 

  25. Maiden L, Takeuchi K, Baur R et al (2008) Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse. Inflamm Bowel Dis 14:1413–1418

    Article  PubMed  Google Scholar 

  26. Emmrich J, Petermann S, Nowak D et al (2007) Leukocytapheresis (LCAP) in the management of chronic active ulcerative colitis–results of a randomized pilot trial. Dig Dis Sci 52:2044–2053

    Article  PubMed  CAS  Google Scholar 

  27. Sakuraba A, Motoya S, Watanabe K et al (2009) An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol 104:2990–2995

    Article  PubMed  Google Scholar 

  28. Sakata Y, Iwakiri R, Amemori S et al (2008) Comparison of the efficacy of granulocyte and monocyte/macrophage adsorptive apheresis and leukocytapheresis in active ulcerative colitis patients: a prospective randomized study. Eur J Gastroenterol Hepatol 20:629–633

    Article  PubMed  CAS  Google Scholar 

  29. Hidaka T, Suzuki K, Kawakami M et al (2001) Dynamic changes in cytokine levels in serum and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis. J Clin Apher 16:74–81

    Article  PubMed  CAS  Google Scholar 

  30. Shimoyama T, Sawada K, Hiwatashi N et al (2001) Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher 16:1–9

    Article  PubMed  CAS  Google Scholar 

  31. Sawada K, Kusugami K, Suzuki Y et al (2005) Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am J Gastroenterol 100:1362–1369

    Article  PubMed  Google Scholar 

  32. Hibi T, Sakuraba A (2005) Is there a role for apheresis in gastrointestinal disorders? Nat Clin Pract Gastroenterol Hepatol 2:200–201

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by the outstanding academic leader's project, Science and Technology Commission of Shanghai (10XD1402600).

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Renji Hospital, Shanghai Institute of Digestive Disease, Shanghai Jiao Tong University School of Medicine, Shanghai, 200001, China

    Mingming Zhu, Xitao Xu, Fang Nie, Jinlu Tong, Shudong Xiao & Zhihua Ran

Authors
  1. Mingming Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xitao Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fang Nie
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jinlu Tong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shudong Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zhihua Ran
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhihua Ran.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhu, M., Xu, X., Nie, F. et al. The efficacy and safety of selective leukocytapheresis in the treatment of ulcerative colitis: a meta-analysis. Int J Colorectal Dis 26, 999–1007 (2011). https://doi.org/10.1007/s00384-011-1193-9

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00384-011-1193-9

Keywords

Search

Navigation